Biosafe acquires ACTS do Brasil's biosafe-related business

NewsGuard 100/100 Score

After a successful partnership of 10 years with its local distributor ACTS do Brasil Ltda., effective immediately Biosafe has acquired all ACTS' Biosafe-related business, which has been spun off into a separate operating entity, Biosafe Brasil Distribuidora Ltda. Terms have not been disclosed.

This move will allow Biosafe to offer an extended range of benefits to customers in Brazil, including direct product support and service.

Today most public and private cord blood banks throughout the country already process with Biosafe's proprietary Sepax technology, which is also used by a number of customers for regenerative medicine applications.

Olivier Waridel, CEO of the Biosafe Group, commented: "We firmly believe in the potential of the Brazilian market and this acquisition will further expand our business in our core markets of stem cell banking, regenerative medicine and bioprocessing. We look forward to strengthening our relationship with existing and future customers, and to assisting them with their development."

Elsewhere in Latin America, Biosafe products are sold through distributors in Mexico, Argentina, Colombia and Chile. Biosafe plans to extend the network to additional countries in the near future.

SOURCE Biosafe Group

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Cross-species liver cell growth could represent a solution to transplant shortage